Rigel Reports Strong Preliminary 2025 Results, Projects 2026 Profitability, and Advances Pipeline
RIGL has more than doubled off its 52-week low of $15.5.
Summary
Rigel Pharmaceuticals announced robust preliminary financial results for Q4 and full-year 2025, projecting positive net income for 2026, alongside encouraging clinical progress across its R289, olutasidenib, and pralsetinib programs.
Key Events · Earnings and Guidance · RIGL
-
Strong 2025 Financial Performance
Preliminary Q4 2025 total revenue reached $69.8 million, with full-year net product sales growing 60% to $232.0 million, and cash reserves doubling to $154.6 million.
-
Positive 2026 Financial Outlook
The company anticipates full-year 2026 total revenue between $275 million and $290 million, and, significantly, projects positive net income for the full year.
-
Advancing Clinical Pipeline
Encouraging Phase 1b data for R289 in lower-risk MDS, continued progress for olutasidenib in AML and glioma, and robust activity for pralsetinib in RET fusion-positive solid tumors were reported.
-
GAVRETO Regulatory Update
The FDA approved a boxed warning for GAVRETO regarding serious infections, though this risk was previously communicated, and a post-marketing commitment was met.
Analysis · RIGL · Life Sciences
This 8-K filing signals a strong operational and financial trajectory for Rigel. The preliminary 2025 results demonstrate significant revenue growth, particularly in net product sales, and a substantial increase in cash reserves. The projection of positive net income for the full year 2026 is a critical milestone, indicating the company's move towards sustained profitability. Furthermore, the updates on R289 in MDS, olutasidenib in AML/glioma, and pralsetinib in various cancers highlight continued clinical advancement and potential for future growth. While a boxed warning was added to GAVRETO's prescribing information, its impact is mitigated by prior communication and the fulfillment of a post-marketing commitment. Investors should view this comprehensive update as highly positive, reinforcing the company's commercial execution and pipeline development.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RIGL was trading at $41.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $807.7M. The 52-week trading range was $15.50 to $52.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.